Table 3.
Laboratory investigation and radiological results at diagnosis of anti-IgLON5 disease in described patients.
| N (%) | |
|---|---|
| Results of radiological investigations | |
| Abnormal 18FDG-PET or SPECT | 11/22 (50.0) |
| Abnormal DaTSCAN | 3/4 (75.0) |
| Brain MRI | |
| Normal or non-specific changes | 107/145 (73.8) |
| Brainstem atrophy | 6/145 (4.2) |
| Cerebellar atrophy | 5/145 (3.4) |
| Hippocampus lesions | 5/145 (3.4) |
| Other abnormalities | 22/145 (15.2) |
| Cerebrospinal fluid investigations | |
| Increased CSF protein content | 56/132 (42.2) |
| Pleocytosis | 26/132 (19.7) |
| Intrathecal immunoglobulin synthesis | 4/16 (25.0) |
| Oligoclonal bands | 9/46 (19.6) |
| Increased total tau | 2/8 (25.0) |
| Increased phosphorylated tau | 4/6 (66.7) |
| Anti-IgLON5 antibodies | |
| Undetectable anti-IgLON5 antibodies in CSF | 12/111 (10.8) |
| HLA genotyping | |
| DRB1*10:01; DQB1*05:01 alleles, n (%) | 61/105 (58.1) |
| Isolated DQB1*05:01, n (%) | 7/105 (6.7) |